Comparative analysis of the effectiveness of neoadjuvant systemic therapy and primary surgical treatment of patients with BRCA - associated triple-negative T1 breast cancer

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: BRCA-associated triple-negative breast cancer does not only have a better overall survival rate, but also a longer recurrence-free period in compatison to patients with sporadic breast cancer. BRCA-associated triple-negative breast cancer shows high sensitivity to chemotherapeutic agents, but the benefit of systemic neoadjuvant therapy for patients with tumor size ≤T1 in triple-negative breast cancer is unclear.

AIM: The aim of the study is to determine the recurrence rate in the patients with BRCA-associated triple-negative breast cancer and to determine the recurrence rate for the group of patients with tumor size ≤T1, depending on the initial treatment.

MATERIALS AND METHODS: The study includes the data of 129 patients diagnosed with BRCA-associated triple-negative breast cancer treated in the period from 2010 to 2022 at the Department of Breast Tumors of the N.N. Petrov National Medical Research Center of Oncology. All the patients have been divided into two groups depending on the initial treatment. Group I included 93 (72.1%) patients whose treatment was started with systemic neoadjuvant therapy, group II, whose initial treatment involved surgery, included 36 (27.9%) patients.

RESULTS: In group I, the number of recurrences was 22 (23.6%), and in group II — 6 (16.6%). Depending on the pathomorphological response to systemic neoadjuvant therapy, the patients of group I have been separated: in the group of patients with a complete pathomorphological response, the number of relapses was 6 (13.3%), and in the group of patients with a partial pathomorphological response — 16 (33.3%). A comparative analysis of 2 groups with tumor size ≤T1 has shown that in group I the number of patients with tumor size ≤T1 was 11 (11.8%) cases, and in group II — 16 (44.4%). Subgroup comparative analysis in group I, taking into account tumor size ≤T1, has shown that recurrence has not been observed when a complete pathomorphological response was achieved in 8 (17.7%) patients, and in the group with partial pathomorphological response in 3 (6.25%) patients with tumor size ≤T1. A relapse has been observed in 1 (2%) case. With clinical tumor size ≤T1 (n = 16), there was no recurrence in group II.

CONCLUSIONS: Patients diagnosed with BRCA-associated triple-negative breast cancer remain at a high risk of recurrence at a later stage of the disease, but this does not apply to patients with a tumor size ≤T1 since the difference in relapse-free survival [AP1] between patients, whose treatment was started with neoadjuvant systemic therapy and patients, whose initial treatment involved surgery % with a clinical tumor size ≤T1, is not confirmed.

Full Text

Restricted Access

About the authors

Diana A. Enaldieva

N.N. Petrov National Medical Research Centre of Oncology

Author for correspondence.
Email: dianaenaldieva932@gmail.com
ORCID iD: 0000-0002-2773-3111
SPIN-code: 2372-3622

PhD student

Russian Federation, Saint Petersburg

Roman V. Donskikh

N.N. Petrov National Medical Research Centre of Oncology

Email: Rdonskih@rambler.ru
ORCID iD: 0000-0002-9391-5327
SPIN-code: 5111-8211

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Petr V. Krivorotko

N.N. Petrov National Medical Research Centre of Oncology

Email: dr.krivorotko@mail.ru
ORCID iD: 0000-0002-4898-9159
SPIN-code: 2448-7506
Scopus Author ID: 36600762900

MD, Dr. Sci. (Med.)

Russian Federation, Saint Petersburg

Evgeny N. Imyanitov

N.N. Petrov National Medical Research Centre of Oncology; Saint Petersburg State Pediatric State Medical University

Email: evgeny@imyanitov.spb.ru
ORCID iD: 0000-0003-4529-7891
SPIN-code: 1909-7323

MD, Dr. Sci. (Med.), Professor, Correspondence Member of the RAS

Russian Federation, Saint Petersburg; Saint Petersburg

Elena K. Zhiltsova

N.N. Petrov National Medical Research Centre of Oncology

Email: ziltsova@yandex.ru
ORCID iD: 0000-0002-2029-4582
SPIN-code: 3045-1704

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Anna P. Sokolenko

N.N. Petrov National Medical Research Centre of Oncology; Saint Petersburg State Pediatric State Medical University

Email: annasokolenko@mail.ru
ORCID iD: 0000-0001-6304-1609
SPIN-code: 1256-9758
Scopus Author ID: 7004209770

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg; Saint Petersburg

Tengiz T. Tabagua

N.N. Petrov National Medical Research Centre of Oncology

Email: tedo8308@mail.ru
ORCID iD: 0000-0003-1471-9473
SPIN-code: 4466-6316

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Nikolay S. Amirov

N.N. Petrov National Medical Research Centre of Oncology

Email: amirovn17@gmail.com
ORCID iD: 0000-0002-2421-3284
SPIN-code: 7793-4290

PhD student

Russian Federation, Saint Petersburg

Roman S. Pesotsky

N.N. Petrov National Medical Research Centre of Oncology

Email: shipmeback@gmail.com
ORCID iD: 0000-0002-2573-2211
Russian Federation, Saint Petersburg

Laysan F. Shaikhelislamova

N.N. Petrov National Medical Research Centre of Oncology

Email: leisyanka97@mail.ru
ORCID iD: 0000-0001-9623-3877
Russian Federation, Saint Petersburg

Alexander S. Emelyanov

N.N. Petrov National Medical Research Centre of Oncology

Email: ae28111992@yandex.ru
ORCID iD: 0000-0002-0528-9937
SPIN-code: 6312-4894
Russian Federation, Saint Petersburg

Viktoria V. Mortada

N.N. Petrov National Medical Research Centre of Oncology

Email: vika-gukova@mail.ru
ORCID iD: 0000-0002-1982-5710
SPIN-code: 3871-8774

PhD student

Russian Federation, Saint Petersburg

Larisa P. Gigolaeva

N.N. Petrov National Medical Research Centre of Oncology

Email: gigosha532@gmail.com
ORCID iD: 0000-0001-7654-4336
SPIN-code: 3521-7448

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Sergey S. Yerechshenko

N.N. Petrov National Medical Research Centre of Oncology

Email: dr.ereschenko@gmail.com
ORCID iD: 0000-0002-5090-7001
SPIN-code: 5957-9137

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Alexander V. Komyakhov

N.N. Petrov National Medical Research Centre of Oncology

Email: komyahov@yandex.ru
ORCID iD: 0000-0002-6598-1669
SPIN-code: 8286-4406

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Kirill S. Nikolaev

N.N. Petrov National Medical Research Centre of Oncology

Email: kirill.nikolaev87@gmail.com
ORCID iD: 0000-0003-3377-6369
SPIN-code: 5627-6696

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Konstantin Yu. Zernov

N.N. Petrov National Medical Research Centre of Oncology

Email: konstantin_zernov@hotmail.com
ORCID iD: 0000-0002-2138-3982
SPIN-code: 9186-5705

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Yana I. Bondarchuk

N.N. Petrov National Medical Research Centre of Oncology

Email: yana_bondarchuk_2015@mail.ru
ORCID iD: 0000-0002-6442-0106
SPIN-code: 9546-3222

PhD student

Russian Federation, Saint Petersburg

Ruslan M. Paltuev

N.N. Petrov National Medical Research Centre of Oncology

Email: paltuev@mail.ru
ORCID iD: 0000-0002-0871-9453
SPIN-code: 9963-3032
Scopus Author ID: 6505715557

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Alexander A. Bessonov

Leningrad Regional Clinical Oncology Center

Email: dr.bessonov@gmail.com
ORCID iD: 0000-0002-6649-7641
SPIN-code: 3553-4670

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Anna S. Artemyeva

N.N. Petrov National Medical Research Centre of Oncology

Email: oinochoya@gmail.com
ORCID iD: 0000-0002-2948-397X
SPIN-code: 5760-5463

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Vladislav V. Semiglazov

N.N. Petrov National Medical Research Centre of Oncology; Pavlov First Saint Petersburg State Medical University

Email: oncology.spbgmu@mail.ru
ORCID iD: 0000-0002-8825-5221
SPIN-code: 6786-9577
Scopus Author ID: 7006310596

д-р мед. наук

Russian Federation, Saint Petersburg; Saint Petersburg

Tatiana Yu. Semiglazova

N.N. Petrov National Medical Research Centre of Oncology

Email: tsemiglazova@mail.ru
ORCID iD: 0000-0002-4305-6691
SPIN-code: 9773-3759
Scopus Author ID: 8562948700

MD, Dr. Sci. (Med.)

Russian Federation, Saint Petersburg

Vladimir F. Semiglazov

N.N. Petrov National Medical Research Centre of Oncology

Email: ssemiglazov@mail.ru
ORCID iD: 0000-0003-0077-9619
SPIN-code: 3874-9539
Scopus Author ID: 18838622600

MD, Dr. Sci. (Med.), Professor, Correspondence Member of the RAS

Russian Federation, Saint Petersburg

Alexsey M. Belyaev

N.N. Petrov National Medical Research Centre of Oncology; North-Western State Medical University named after I.I. Mechnikov

Email: bam281060@yandex.ru
ORCID iD: 0000-0001-5580-4821
SPIN-code: 9445-9473

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg; Saint Petersburg

References

  1. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science (New York, NY). 1990;250(4988):1684–1689. doi: 10.1126/science.2270482
  2. Zlokachestvennye novoobrazovaniya v Rossii v 2020 godu (zabolevaemost’ i smertnost’). Ed. by A.D. Kaprin, V.V. Starinski, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena; 2021. 252 p. (In Russ.)
  3. Imyanitov EN. Nasledstvennyi rak molochnoi zhelezy. Practical oncology. 2010;11(4):258–266. (In Russ.)
  4. Graffeo R, Livraghi L, Pagani O, et al. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Res Treat. 2016;160(3):393–410. doi: 10.1007/s10549-016-4003-9
  5. Kast K, Rhiem K, Wappenschmidt B, et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet. 2016;53(7):65–71. doi: 10.1136/jmedgenet-2015-103672
  6. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer — current status and future directions. Ann Oncol. 2009;20(12):1913-1927. doi: 10.1093/annonc/mdp492
  7. Sokolenko AP, Preobrazhenskaya EV, Aleksakhina SN, et al. Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients. Cancer Lett. 2015;359(2):259–261. doi: 10.1016/j.canlet.2015.01.022
  8. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130. doi: 10.1086/375033
  9. Antoniou AC, Gayther SA, Stratton JF, et al. Risk models for familial ovarian and breast cancer. Genet Epidemiol. 2000;18(2):173–190. doi: 10.1002/(SICI)1098-2272(200002)18:2<173::AID-GEPI6>3.0.CO;2-R
  10. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–646. doi: 10.1126/science.1088759
  11. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812–822. doi: 10.1093/jnci/djt095
  12. Zhu Y, Wu J, Zhang C, et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget. 2016;7(43):70113–70127. doi: 10.18632/oncotarget.12158
  13. Lee E-H, Park SK, Park B, et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010;122(1):11–25. doi: 10.1007/s10549-010-0859-2
  14. Zhong Q, Peng H-L, Zhao X, et al. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival. a meta-analysis. Clin Cancer Res. 2015;21(1):211–220. doi: 10.1158/1078-0432.CCR-14-1816
  15. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science (New York, NY). 1994;265(5181):2088–2090. doi: 10.1126/science.8091231
  16. Baretta Z, Mocellin S, Goldin E, et al. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore). 2016;95(40):e4975. doi: 10.1097/MD.0000000000004975
  17. Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169–180. doi: 10.1016/S1470-2045(17)30891-4
  18. Bignon L, Fricker J, Nogues C, et al. Efficacy of anthracycline/taxanebased neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers. Breast J. 2018;24(3):269–277. doi: 10.1111/tbj.12887
  19. Anders CK, Winer EP, Ford JM, et al. Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer. Clin Cancer Res. 2010;16(19):4702–4710. doi: 10.1158/1078-0432.CCR-10-0939
  20. Hoyer J, Vasileiou G, Uebe S, et al. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. BMC Cancer. 2018;18(1):926. doi: 10.1186/s12885-018-4821-8
  21. Mavaddat N, Barrowdale D, Andrulis I, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134–147. doi: 10.1158/1055-9965.EPI-11-0775
  22. Tsai J, Bertoni D, Hernandez-Boussard T, et al. Lymph node ratio analysis after neoadjuvant chemotherapy is prognostic in hormone receptor-positive and triple-negative breast cancer. Ann Surg Oncol. 2016;23(10):3310–3316. doi: 10.1245/s10434-016-5319-8
  23. Singh S, Numan A, Agrawal N, et al. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care. Int Immunopharmacol. 2020;83:106417. doi: 10.1016/j.intimp.2020.106417
  24. Kohler BA, Sherman RL, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6):djv048. doi: 10.1093/jnci/djv048
  25. Geyer F, Geyer FC, Pareja F, Weigelt B, et al. The spectrum of triple-negative breast disease: High- and low- grade lesions. Am J Pathol. 2017;187(10):2139–2151. doi: 10.1016/j.ajpath.2017.03.016
  26. Khosravi-Shahi P, Cabezón-Gutiérrez L, Custodio-Cabello S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol. 2018;14(1):32–39. doi: 10.1111/ajco.12748
  27. Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: Subtypes and treatment strategies. Cancer Cell. 2019;35(3):428–440. doi: 10.1016/j.ccell.2019.02.001
  28. Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690. doi: 10.1038/nrclinonc.2016.66
  29. Palomba G, Budroni M, Olmeo N, et al. Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia. Oncol lett. 2014;7(4):948–952. doi: 10.3892/ol.2014.1834
  30. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304–311. doi: 10.1200/JCO.2014.57.1414
  31. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–1089. doi: 10.1158/1078-0432.CCR-10-2560
  32. Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118(11):2787–2795. doi: 10.1002/cncr.26576
  33. Zhang J, Sun J, Chen J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5,931 Chinese women with breast cancer. Breast Cancer Res Treat. 2016;158(3):455–462. doi: 10.1007/s10549-016-3902-0
  34. Von Minckwitz G, Hahnen E, Fasching PA, et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. J Clin Oncol. 2014;32(15 suppl):1005. doi: 10.1200/jco.2014.32.15_suppl.1005
  35. Gonzalez-Rivera M, Lobo M, Lopez-Tarruella S, et al. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Breast Cancer Res Treat. 2016;156(3):507–515. doi: 10.1007/s10549-016-3792-1
  36. Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(1):71–80. doi: 10.1007/s10549-015-3293-7
  37. Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145(3):707–714. doi: 10.1007/s10549-014-2980-0
  38. Wang C, Chen Z, Zhou Y, et al. T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes. Gland Surg. 2021;10(3):943–952. doi: 10.21037/gs-20-762

Supplementary files

There are no supplementary files to display.


Copyright (c) 2023 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies